HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G licensing deal

This article was originally published in The Rose Sheet

Executive Summary

GMP Companies will use Procter & Gamble's anti-infective technology to develop antimicrobial hand rub solution and surgical scrub and preparation products under a licensing agreement between the two firms announced Feb. 5. The anti-infective technology comprises a combination of active ingredients not currently available in the health care market, and was found to immediately kill deadly viruses, bacteria and other infectious agents in preliminary testing, firm claims. GMP plans to "broadly commercialize" the technology for use in health care settings, including hospitals and doctors' offices. Under the terms of the agreement, GMP will sell medical formulations of the technology to commercial and industrial customers, while P&G retains the rights to develop and market a retail version. Move is in line with P&G's strategy to license untapped technologies...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS011890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel